Exemestane

• Individualized everolimus therapy in metastatic breast cancer Pending
  2023-505590-33-06 Phase II 1 country Orszagos Onkologiai Intezet
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending
  2024-519087-41-00 Phase III 1 country IRCCS Ospedale Policlinico San Martino
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 Phase III 7 countries Unicancer
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 Phase III 6 countries Eli Lilly & Co.
• Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6… Pending
  2025-522848-40-00 Phase IV 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 Phase II 1 country Unicancer
• The combination of Elacestrant and exemestane for patients with pretreated metastatic breast cancer expressing hormone receptors and non-exp… Recruiting
  2024-519792-25-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 Phase III 5 countries Unicancer
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting
  2024-512360-55-00 Phase II 9 countries Medica Scientia Innovation Research S.L.
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 Phase III 16 countries Eli Lilly & Co.
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting
  2025-520566-22-00 Phase III 14 countries Pfizer Inc.
• Randomized double blind phase 2 trial of baby exemestane versus baby tamoxifen in postmenopausal women at high risk for breast cancer Recruiting
  2024-520004-26-00 Phase II 2 countries Ente Ospedaliero Ospedali Galliera Di Genova
• Optimizing endocrine treatment > 5 years after surgery for breast cancer patients: a registry-based randomized clinical trial Recruiting
  2023-506135-14-00 Phase III/IV 1 country Region Oerebro Laen
• A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015) Recruiting
  2024-519563-18-00 Phase II/III 1 country Merck Sharp & Dohme LLC
• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I… Recruiting
  2023-505758-17-00 Phase II 2 countries Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting
  2024-515445-42-00 Phase III 15 countries Stemline Therapeutics Inc.
• Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread… Recruiting
  2024-511497-79-00 Phase II 2 countries Puma Biotechnology Inc.
• The RED FLASH study Recruiting
  2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting
  2023-505871-63-00 Phase III 13 countries Olema Pharmaceuticals Inc.
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting
  2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting
  2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen

Showing 1–24 of 48 trials